Aclaris Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript - Thomson StreetEvents

Aclaris Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Aclaris Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript - Thomson StreetEvents
Aclaris Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Published Jun 11, 2025
13 pages (6998 words) — Published Jun 11, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ACRS.OQ presentation 11-Jun-25 5:20pm GMT

  
Brief Excerpt:

... Welcome to day-three of the Goldman Sachs Annual Healthcare Conference. I'm thrilled to be joined today by the team from Aclaris. Maybe I'll let you guys introduce yourselves first and then give us a bit of an overview on the company. Hugh Davis ...

  
Report Type:

Transcript

Source:
Company:
Aclaris Therapeutics Inc
Ticker
ACRS.OQ
Time
5:20pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Aclaris Therapeutics Inc ATI-052 Interim Phase 1a Clinical Trial Results Call Transcript – 2026-01-06 – US$ 106.00 – Edited Transcript of ACRS.OQ conference call or presentation 6-Jan-26 1:00pm GMT

Aclaris Therapeutics Inc R&D Day Transcript – 2025-10-14 – US$ 54.00 – Edited Transcript of ACRS.OQ corporate analyst meeting</ 14-Oct-25 1:00pm GMT

Aclaris Therapeutics Inc ATI-2138 Phase 2a Results and ITK Franchise Update Call Transcript – 2025-07-29 – US$ 54.00 – Edited Transcript of ACRS.OQ conference call or presentation 29-Jul-25 9:00pm GMT

Aclaris Therapeutics Inc Annual Shareholders Meeting Transcript – 2025-06-05 – US$ 54.00 – Edited Transcript of ACRS.OQ shareholder or annual meeting 5-Jun-25 1:00pm GMT

Aclaris Therapeutics Inc Corporate Update Transcript – 2024-11-18 – US$ 54.00 – Edited Transcript of ACRS.OQ corporate analyst meeting</ 18-Nov-24 1:30pm GMT

Aclaris Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript – 2024-06-11 – US$ 54.00 – Edited Transcript of ACRS.OQ presentation 11-Jun-24 3:20pm GMT

Aclaris Therapeutics Inc Annual Shareholders Meeting Transcript – 2024-06-06 – US$ 54.00 – Edited Transcript of ACRS.OQ shareholder or annual meeting 6-Jun-24 1:00pm GMT

Aclaris Therapeutics Inc to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results Call Transcript – 2023-11-13 – US$ 54.00 – Edited Transcript of ACRS.OQ conference call or presentation 13-Nov-23 1:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Aclaris Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript" Jun 11, 2025. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Aclaris-Therapeutics-Inc-at-Goldman-Sachs-Global-Healthcare-Conference-T16395028>
  
APA:
Thomson StreetEvents. (2025). Aclaris Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript Jun 11, 2025. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Aclaris-Therapeutics-Inc-at-Goldman-Sachs-Global-Healthcare-Conference-T16395028>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.